CreativeOne Wealth LLC Has $222,000 Position in Novartis AG (NYSE:NVS)

CreativeOne Wealth LLC cut its stake in Novartis AG (NYSE:NVS - Free Report) by 66.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,280 shares of the company's stock after selling 4,492 shares during the period. CreativeOne Wealth LLC's holdings in Novartis were worth $222,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of NVS. Human Investing LLC acquired a new position in Novartis in the fourth quarter valued at approximately $25,000. Union Bancaire Privee UBP SA acquired a new position in shares of Novartis during the 4th quarter worth about $27,000. Kestra Investment Management LLC acquired a new position in Novartis during the fourth quarter valued at approximately $47,000. Clearstead Trust LLC bought a new stake in Novartis in the fourth quarter valued at approximately $51,000. Finally, Brooklyn Investment Group bought a new position in shares of Novartis during the fourth quarter worth $55,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. BNP Paribas raised Novartis to a "strong-buy" rating in a research note on Tuesday, April 15th. Barclays reaffirmed an "underweight" rating on shares of Novartis in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft raised Novartis from a "hold" rating to a "buy" rating in a research note on Tuesday, February 4th. UBS Group reiterated a "neutral" rating on shares of Novartis in a report on Thursday, February 13th. Finally, StockNews.com upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 8th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $123.38.

Novartis Stock Up 0.9 %

Shares of Novartis stock traded up $1.03 during trading hours on Thursday, reaching $111.16. 1,435,662 shares of the company's stock were exchanged, compared to its average volume of 1,548,703. The stock has a market cap of $234.82 billion, a P/E ratio of 18.90, a P/E/G ratio of 1.70 and a beta of 0.56. The company has a 50 day moving average of $109.45 and a two-hundred day moving average of $106.26. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. Novartis AG has a fifty-two week low of $96.06 and a fifty-two week high of $120.92.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, sell-side analysts forecast that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Dividend Announcement

The company also recently declared a dividend, which was paid on Wednesday, March 12th. Shareholders of record on Wednesday, March 12th were given a dividend of $3.8695 per share. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's dividend payout ratio (DPR) is currently 44.05%.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.